<DOC>
	<DOC>NCT00517491</DOC>
	<brief_summary>The purpose of the protocol is to evaluate the correlation between plasma lanreotide levels and Growth Hormone (GH)/Insulin Like Growth Factor 1 (IGF-1) dynamics and clinical improvement in patients with acromegaly treated with lanreotide Autogel (Somatuline ATG)</brief_summary>
	<brief_title>Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Patient on treatment with octreotide LAR 20 mg administered every 28 days for at least 3 months prior to visit 1. Patient must have serum GH level ≤ 2.5 ng/mL and serum IGF1 ≤ 1.3 ULN, 28 days after their last injection of octreotide LAR 20 mg at visit 1. Patients must have serum GH level &gt; 2.5 ng/mL AND serum IGF1 level &gt; 1.3 ULN, 6 or 8 weeks after their last injection of octreotide LAR 20 mg. The patient has received pituitary radiation therapy of any kind at any time prior to visit 1. The patient has received pituitary surgery within 3 months prior to visit 1. The patient's serum creatinine is higher than 150 µmol/l.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>